Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jun 2022: Trial registered, NCT05404139
  2. 24 May 2023: Trial started, NCT05404139

The trials

NCT05404139: Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

State
Under way
Phase
Phase 2
People
352 planned
Started
24 May 2023
Primary completion
Feb 2031
Arms
Arm 4: Study Treatment (Abiraterone + Atorvastatin)
Results
None posted
  1. 3 Jun 2022: Trial registered
  2. 24 May 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.